Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Hormone. University of Liverpool, Liverpool, United Kingdom



Survival: 23.5 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Hormone
   
Drugs:
Country: United Kingdom
   
City/State/Province: Liverpool
   
Hospital: University of Liverpool
   
Journal: Link
   
Date: 5/2012

Description:
Patients:
This study involved 39 chronic lymphocytic leukemia patients who had a genetic deletion of the TP53 gene. The median patient age was 62 years and 56% were male.

Treatment:
Patients were threated with the biologic therapy agent called alemtuzumab, which is an anti-CD52 monoclonal antibody that targets cancer cells to be killed by the immune system. Patients were also treated with the corticosteroid (hormone) methylprednisolone.

Toxicities:
Treatment-related deaths due to infection and brain hemorrhage were reported. Grade 4 neutropenia and grade 3 fatigue were also reported.

Results:
The median overall survival was 23.5 months.

Support:
This study was partially supported by Bayer-Schering Pharma.

Correspondence: Dr. Andrew Pettitt, email: arp@liverpool.ac.uk

E-mail to a Friend Email Physician More Information